Immunotherapeutic strategies for bladder cancer

References

• Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46:765 - 81; http://dx.doi.org/10.1016/j.ejca.2009.12.014; PMID: 20116997
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10 - 29; http://dx.doi.org/10.3322/caac.20138; PMID: 22237781
   PubMed Web of Science ®Google Scholar
• Nielsen ME, Smith AB, Meyer AM, Kuo TM, Tyree S, Kim WY, Milowsky MI, Pruthi RS, Millikan RC. Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006. Cancer 2014; 120:86 - 95; http://dx.doi.org/10.1002/cncr.28397; PMID: 24122346
   PubMed Web of Science ®Google Scholar
• Kiriluk KJ, Prasad SM, Patel AR, Steinberg GD, Smith ND. Bladder cancer risk from occupational and environmental exposures. Urol Oncol 2012; 30:199 - 211; http://dx.doi.org/10.1016/j.urolonc.2011.10.010; PMID: 22385990
   PubMed Web of Science ®Google Scholar
• Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, Rouprêt M, European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59:997 - 1008; http://dx.doi.org/10.1016/j.eururo.2011.03.017; PMID: 21458150
   PubMed Web of Science ®Google Scholar
• De Boer EC, De Jong WH, Van Der Meijden AP, Steerenberg PA, Witjes JA, Vegt PD, Debruyne FM, Ruitenberg EJ. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother 1991; 33:411 - 6; http://dx.doi.org/10.1007/BF01741603; PMID: 1878894
   PubMed Web of Science ®Google Scholar
• Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993; 150:1018 - 23; PMID: 8102183
   PubMed Web of Science ®Google Scholar
• Riemensberger J, Böhle A, Brandau S. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 2002; 127:20 - 6; http://dx.doi.org/10.1046/j.1365-2249.2002.01734.x; PMID: 11882028
   PubMed Web of Science ®Google Scholar
• Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, Abbou CC, Chopin DK. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol 2002; 167:364 - 7; http://dx.doi.org/10.1016/S0022-5347(05)65469-9; PMID: 11743357
   PubMed Web of Science ®Google Scholar
• de Reijke TM, de Boer EC, Kurth KH, Schamhart DH. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996; 155:477 - 82; http://dx.doi.org/10.1016/S0022-5347(01)66424-3; PMID: 8558640
   PubMed Web of Science ®Google Scholar
• Nadler R, Luo Y, Zhao W, Ritchey JK, Austin JC, Cohen MB, O’Donnell MA, Ratliff TL. Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity. Clin Exp Immunol 2003; 131:206 - 16; PMID: 12562379
   PubMed Web of Science ®Google Scholar
• Luo Y, Chen X, O’Donnell MA. Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. Cytokine 2003; 21:17 - 26; http://dx.doi.org/10.1016/S1043-4666(02)00490-8; PMID: 12668155
   PubMed Web of Science ®Google Scholar
• Bockholt NA, Knudson MJ, Henning JR, Maymí JL, Weady P, Smith GJ 3rd, Eisenbraun MD, Fraser JD, O’Donnell MA, Luo Y. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer. J Urol 2012; 187:2228 - 35; http://dx.doi.org/10.1016/j.juro.2012.01.030; PMID: 22503050
   PubMed Web of Science ®Google Scholar
• Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 2006; 175:2004 - 10; http://dx.doi.org/10.1016/S0022-5347(06)00264-3; PMID: 16697786
   PubMed Web of Science ®Google Scholar
• Kresowik TP, Griffith TS. Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy 2009; 1:281 - 8; http://dx.doi.org/10.2217/1750743X.1.2.281; PMID: 20046960
   PubMed Web of Science ®Google Scholar
• Sylvester RJ. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer. Int J Urol 2011; 18:113 - 20; http://dx.doi.org/10.1111/j.1442-2042.2010.02678.x; PMID: 21091799
   PubMed Web of Science ®Google Scholar
• Giannarini G, Birkhäuser FD, Recker F, Thalmann GN, Studer UE. Bacillus Calmette-Guérin Failure in Patients with Non-Muscle-invasive Urothelial Carcinoma of the Bladder May Be Due to the Urologist’s Failure to Detect Urothelial Carcinoma of the Upper Urinary Tract and Urethra. Eur Urol 2013; Forthcoming http://dx.doi.org/10.1016/j.eururo.2013.09.049; PMID: 24144432
   PubMed Web of Science ®Google Scholar
• Biot C, Rentsch CA, Gsponer JR, Birkhäuser FD, Jusforgues-Saklani H, Lemaître F, Auriau C, Bachmann A, Bousso P, Demangel C, et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med 2012; 4:37ra72; http://dx.doi.org/10.1126/scitranslmed.3003586; PMID: 22674550
   PubMed Web of Science ®Google Scholar
• Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. Lancet Oncol 2012; 13:e32 - 42; http://dx.doi.org/10.1016/S1470-2045(11)70155-3; PMID: 22225723
   PubMed Web of Science ®Google Scholar
• Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 2007; 104:3967 - 72; http://dx.doi.org/10.1073/pnas.0611618104; PMID: 17360461
   PubMed Web of Science ®Google Scholar
• Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, Jungbluth AA. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 2006; 12:5442 - 7; http://dx.doi.org/10.1158/1078-0432.CCR-06-0527; PMID: 17000678
   PubMed Web of Science ®Google Scholar
• Nishiyama T, Tachibana M, Horiguchi Y, Nakamura K, Ikeda Y, Takesako K, Murai M. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res 2001; 7:23 - 31; PMID: 11205913
   PubMed Web of Science ®Google Scholar
• Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother 2008; 31:849 - 57; http://dx.doi.org/10.1097/CJI.0b013e3181891574; PMID: 18833002
   PubMed Web of Science ®Google Scholar
• Obara W, Ohsawa R, Kanehira M, Takata R, Tsunoda T, Yoshida K, Takeda K, Katagiri T, Nakamura Y, Fujioka T. Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn J Clin Oncol 2012; 42:591 - 600; http://dx.doi.org/10.1093/jjco/hys069; PMID: 22636067
   PubMed Web of Science ®Google Scholar
• Nolz JC, Starbeck-Miller GR, Harty JT. Naive, effector and memory CD8 T-cell trafficking: parallels and distinctions. Immunotherapy 2011; 3:1223 - 33; http://dx.doi.org/10.2217/imt.11.100; PMID: 21995573
   PubMed Web of Science ®Google Scholar
• Nardelli-Haefliger D, Dudda JC, Romero P. Vaccination route matters for mucosal tumors. Sci Transl Med 2013; 5:fs4; http://dx.doi.org/10.1126/scitranslmed.3005638; PMID: 23408051
   PubMed Web of Science ®Google Scholar
• Sandoval F, Terme M, Nizard M, Badoual C, Bureau MF, Freyburger L, Clement O, Marcheteau E, Gey A, Fraisse G, et al. Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 2013; 5:72ra20; http://dx.doi.org/10.1126/scitranslmed.3004888; PMID: 23408053
   PubMed Web of Science ®Google Scholar
• Decrausaz L, Domingos-Pereira S, Duc M, Bobst M, Romero P, Schiller JT, Jichlinski P, Nardelli-Haefliger D. Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors. Int J Cancer 2011; 129:762 - 72; http://dx.doi.org/10.1002/ijc.25973; PMID: 21384340
   PubMed Web of Science ®Google Scholar
• Decrausaz L, Revaz V, Bobst M, Corthésy B, Romero P, Nardelli-Haefliger D. Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice. Int J Cancer 2010; 126:2469 - 78; PMID: 19816937
   PubMed Web of Science ®Google Scholar
• Domingos-Pereira S, Derré L, Warpelin-Decrausaz L, Haefliger JA, Romero P, Jichlinski P, Nardelli-Haefliger D. Intravaginal and Subcutaneous Immunization Induced, Vaccine Specific CD8 T Cells and Tumor Regression in the Bladder. J Urol 2013; Forthcoming http://dx.doi.org/10.1016/j.juro.2013.08.009; PMID: 23954582
   PubMed Web of Science ®Google Scholar
• Naz RK. Female genital tract immunity: distinct immunological challenges for vaccine development. J Reprod Immunol 2012; 93:1 - 8; http://dx.doi.org/10.1016/j.jri.2011.09.005; PMID: 22154945
   PubMed Web of Science ®Google Scholar
• Chan CY, St John AL, Abraham SN. Mast cell interleukin-10 drives localized tolerance in chronic bladder infection. Immunity 2013; 38:349 - 59; http://dx.doi.org/10.1016/j.immuni.2012.10.019; PMID: 23415912
   PubMed Web of Science ®Google Scholar
• Domingos-Pereira S, Decrausaz L, Derré L, Bobst M, Romero P, Schiller JT, Jichlinski P, Nardelli-Haefliger D. Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Mucosal Immunol 2013; 6:393 - 404; http://dx.doi.org/10.1038/mi.2012.83; PMID: 22968420
   PubMed Web of Science ®Google Scholar
• Decrausaz L, Pythoud C, Domingos-Pereira S, Derré L, Jichlinski P, Nardelli-Haefliger D. Intravaginal live attenuated Salmonella increase local antitumor vaccine-specific CD8(+) T cells. Oncoimmunology 2013; 2:e22944; http://dx.doi.org/10.4161/onci.22944; PMID: 23483225
   PubMedGoogle Scholar
• Messing EM. Why should we increase public awareness of bladder cancer, and how can we do it?. Nat Clin Pract Urol 2008; 5:117; http://dx.doi.org/10.1038/ncpuro1061; PMID: 18322472
   PubMedGoogle Scholar